Literature DB >> 20972473

The Immune Tolerance Network at 10 years: tolerance research at the bedside.

Jeffrey A Bluestone1, Hugh Auchincloss, Gerald T Nepom, Daniel Rotrosen, E William St Clair, Laurence A Turka.   

Abstract

Immune tolerance-inducing therapies reprogramme immune cells to eliminate pathogenic immune responses while preserving protective immunity. The Immune Tolerance Network (ITN), sponsored by the US National Institutes of Health, was established in 1999 to evaluate new tolerance-inducing therapies and carry out mechanistic studies using a unique interactive approach in partnership with industry, academia and foundations. Ten years later, the ITN has carried out approximately 36 clinical trials and tolerance studies examining innovative tolerogenic approaches in the settings of allergy, autoimmune diseases and organ transplantation. ITN investigators have published more than 80 original research papers based on this work. This Timeline article summarizes the progress and challenges of clinical research in the ITN.

Entities:  

Mesh:

Year:  2010        PMID: 20972473     DOI: 10.1038/nri2869

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  43 in total

1.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

2.  In vivo biotinylation of the major histocompatibility complex (MHC) class II/peptide complex by coexpression of BirA enzyme for the generation of MHC class II/tetramers.

Authors:  Junbao Yang; Andrés Jaramillo; Ruili Shi; William W Kwok; T Mohanakumar
Journal:  Hum Immunol       Date:  2004-07       Impact factor: 2.850

3.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

4.  International trial of the Edmonton protocol for islet transplantation.

Authors:  A M James Shapiro; Camillo Ricordi; Bernhard J Hering; Hugh Auchincloss; Robert Lindblad; R Paul Robertson; Antonio Secchi; Mathias D Brendel; Thierry Berney; Daniel C Brennan; Enrico Cagliero; Rodolfo Alejandro; Edmond A Ryan; Barbara DiMercurio; Philippe Morel; Kenneth S Polonsky; Jo-Anna Reems; Reinhard G Bretzel; Federico Bertuzzi; Tatiana Froud; Raja Kandaswamy; David E R Sutherland; George Eisenbarth; Miriam Segal; Jutta Preiksaitis; Gregory S Korbutt; Franca B Barton; Lisa Viviano; Vicki Seyfert-Margolis; Jeffrey Bluestone; Jonathan R T Lakey
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

5.  Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice.

Authors:  Alex Rabinovitch; Wilma L Suarez-Pinzon; A M James Shapiro; Ray V Rajotte; Robert Power
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

6.  Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Authors:  Kevan C Herold; Stephen Gitelman; Carla Greenbaum; Jennifer Puck; William Hagopian; Peter Gottlieb; Peter Sayre; Peter Bianchine; Emelita Wong; Vicki Seyfert-Margolis; Kasia Bourcier; Jeffrey A Bluestone
Journal:  Clin Immunol       Date:  2009-05-14       Impact factor: 3.969

7.  HLA-mismatched renal transplantation without maintenance immunosuppression.

Authors:  Tatsuo Kawai; A Benedict Cosimi; Thomas R Spitzer; Nina Tolkoff-Rubin; Manikkam Suthanthiran; Susan L Saidman; Juanita Shaffer; Frederic I Preffer; Ruchuang Ding; Vijay Sharma; Jay A Fishman; Bimalangshu Dey; Dicken S C Ko; Martin Hertl; Nelson B Goes; Waichi Wong; Winfred W Williams; Robert B Colvin; Megan Sykes; David H Sachs
Journal:  N Engl J Med       Date:  2008-01-24       Impact factor: 91.245

8.  Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.

Authors:  Tim A Weaver; Ali H Charafeddine; Avinash Agarwal; Alexandra P Turner; Maria Russell; Frank V Leopardi; Robert L Kampen; Linda Stempora; Mingqing Song; Christian P Larsen; Allan D Kirk
Journal:  Nat Med       Date:  2009-07-05       Impact factor: 53.440

9.  Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.

Authors:  Sven Klunker; Lavina R Saggar; Vicki Seyfert-Margolis; Adam L Asare; Thomas B Casale; Stephen R Durham; James N Francis
Journal:  J Allergy Clin Immunol       Date:  2007-07-12       Impact factor: 10.793

10.  Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients.

Authors:  Manuela Battaglia; Angela Stabilini; Barbara Migliavacca; Jutta Horejs-Hoeck; Thomas Kaupper; Maria-Grazia Roncarolo
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

View more
  23 in total

1.  Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications.

Authors:  Veronica Marrella; Pietro L Poliani; Elena Fontana; Anna Casati; Virginia Maina; Barbara Cassani; Francesca Ficara; Manuela Cominelli; Francesca Schena; Marianna Paulis; Elisabetta Traggiai; Paolo Vezzoni; Fabio Grassi; Anna Villa
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

Review 2.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

3.  Engineering antigens for in situ erythrocyte binding induces T-cell deletion.

Authors:  Stephan Kontos; Iraklis C Kourtis; Karen Y Dane; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

4.  MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection.

Authors:  Elodie Picarda; Séverine Bézie; Vanessa Venturi; Klara Echasserieau; Emmanuel Mérieau; Aurélie Delhumeau; Karine Renaudin; Sophie Brouard; Karine Bernardeau; Ignacio Anegon; Carole Guillonneau
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

Review 5.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

Review 6.  The battle against immunopathology: infectious tolerance mediated by regulatory T cells.

Authors:  David M Gravano; Dario A A Vignali
Journal:  Cell Mol Life Sci       Date:  2011-12-29       Impact factor: 9.261

7.  Genetic interaction between two insulin-dependent diabetes susceptibility loci, Idd2 and Idd13, in determining immunoregulatory DN T cell proportion.

Authors:  Roxanne Collin; Kathy Doyon; Victor Mullins-Dansereau; Martin Karam; Geneviève Chabot-Roy; Erin E Hillhouse; Alexandre Orthwein; Sylvie Lesage
Journal:  Immunogenetics       Date:  2018-04-25       Impact factor: 2.846

8.  Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.

Authors:  Angela C Sosa; Barbara Kariuki; Qi Gan; Alan P Knutsen; Clifford J Bellone; Miguel A Guzmán; Luis A Barrera; Shunji Tomatsu; Anil K Chauhan; Eric Armbrecht; Adriana M Montaño
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

9.  Translation of Digital Health Technologies to Advance Precision Medicine: Informing Regulatory Science.

Authors:  Joan E Adamo; Robert V Bienvenu Ii; Felipe Dolz; Michael Liebman; Wendy Nilsen; Scott J Steele
Journal:  Digit Biomark       Date:  2020-02-07

10.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.

Authors:  Hye Sun Kuehn; Weiming Ouyang; Bernice Lo; Elissa K Deenick; Julie E Niemela; Danielle T Avery; Jean-Nicolas Schickel; Dat Q Tran; Jennifer Stoddard; Yu Zhang; David M Frucht; Bogdan Dumitriu; Phillip Scheinberg; Les R Folio; Cathleen A Frein; Susan Price; Christopher Koh; Theo Heller; Christine M Seroogy; Anna Huttenlocher; V Koneti Rao; Helen C Su; David Kleiner; Luigi D Notarangelo; Yajesh Rampertaap; Kenneth N Olivier; Joshua McElwee; Jason Hughes; Stefania Pittaluga; Joao B Oliveira; Eric Meffre; Thomas A Fleisher; Steven M Holland; Michael J Lenardo; Stuart G Tangye; Gulbu Uzel
Journal:  Science       Date:  2014-09-11       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.